Full Press Release Details
Updated corporate presentation
New York/London, 26 January 2021 - Tiziana
Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused
on innovative therapeutics for oncology, inflammation, and infectious diseases, has today published an updated presentation to
its website at https://ir.tizianalifesciences.com/presentation providing an update with respect to an overview of its current clinical
The presentation contains no new material
information but gives an overview of all of the Company's current and active development pipeline, consolidating information the
subject of previous announcements, including the potential of Foralumab as a lymphodepletion agent in CAR-T therapies for cancer.
The Company's budgeted expenditure for
the full year 2021 remains $30m and budgeted expenditure for 2022 remains $28m; in both cases the expenditure totals include all
clinical and general and administrative expenditure. Cash and cash equivalents as at December 31, 2020 stood at US$62m.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed
(NASDAQ: TLSA & LSE: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat
human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating
Phase 2 studies with orally administered Foralumab for Crohn's Disease and nasally administered Foralumab for progressive
multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.
This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's
Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
RedChip Companies Inc.